A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells - PubMed (original) (raw)
doi: 10.1038/leu.2010.300. Epub 2011 Jan 14.
E Battista, F Conforti, P Neri, M T Di Martino, M Rossi, U Foresta, E Piro, F Ferrara, A Amorosi, N Bahlis, K C Anderson, N Munshi, P Tagliaferri, F Causa, P Tassone
- PMID: 21233838
- PMCID: PMC3089835
- DOI: 10.1038/leu.2010.300
Free PMC article
A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells
T Calimeri et al. Leukemia. 2011 Apr.
Free PMC article
No abstract available
Figures
Figure 1
(A) SEM analysis of a PCLS ( × 65 (1), × 500 (2), × 650 (3) and × 1200 (4) magnification) shows interconnected large and small pores (white bars=1 mm (1), 200 μm (2), 100 μm (3) and 50 μm (4)). (B) Comparative SEM analysis ( × 150 magnification) between a synthetic PCLS (upper panel) and a surgical sample of human femur adult bone (lower panel) shows similar microarchitecture (white bars=500 μm). Surface morphology was studied by a Leica Cambridge (Stereoscan S440) SEM (Cambridge, UK) at an accelerating potential of 20 kV. (C) H&E staining of adherent OP9 mouse stromal cells at 3 weeks after scaffold implant in mice. (D–F) SEM analysis ( × 3500 magnification) (d), H&E staining (e) and confocal laser scanning microscopy (f) show adherence within a PCLS of human BMSCs, obtained from two different patients (pt #3, (a); pt #7, (b) See Table 1), 1 week after implant in mice. (G) Flow chart diagram. Schematic representation of experimental methodology.
Figure 2
(a) Histological and immunohistochemical (anti-CD138/MI15 (Dako, Dako Itala S.p.A., Milano, Italy), anti-κ (Dako) and anti-λ (Dako)) analysis of retrieved PCLSs. Line 1 shows unselected BMMCs; line 2 shows selected CD138+ on heterologous BMSCs; line 3 shows selected CD138+ from PB of a PCL patient on heterologous BMSCs; and line 4 shows IL-6-dependent INA-6 MM cells on heterologous BMSCs. Anti-human κ-light chains and anti-human λ-light chains were used (Dako). Dilutions were 1:15 000 for κ-light chains and 1:10 000 for λ-light chains. (b) Ki-67 staining of MM-bearing PCLSs retrieved 3–4 months after cell injection. (c, d) Kinetics of appearance of paraproteins in sera from representative SCID-synth-hu mice engrafted with samples from MM patients. A code for each patient sample is provided according to Table 1. Left panel includes seven samples from patients with whole paraprotein (ELISA, GenWay Biotech Inc., San Diego, CA, USA); right panel includes two patients with light chain MM (ELISA, Bethyl Laboratories Inc., Montgomery, TX, USA).
Figure 3
(a) SCID-synth-hu mice were treated intraperitoneally with bortezomib (1 mg/kg)+dexamethasone (1 mg/kg). The black arrows indicate the time of treatment. (b) H&E staining of a MM-bearing PCLS, engrafted with primary MM cells, following Bort+Dex treatment showed diffuse stromal and intracellular calcification demonstrating massive apoptosis. (c) (1) H&E staining of a retrieved PCLS showed vessels of variable size (black circles). (2) Immunohistochemistry of a PCLS coated with BMSCs demonstrated reactivity with an anti-CD31/JC70A (Dako) specific for human CD31 (black arrow). Appropriate positive control tissues were added on each automated immunohistochemistry run to confirm antibody specificity. Negative control section included normal rabbit serum as a substitute for the primary antibody. (3) H&E staining of a retrieved PCLS engrafted with BMMCs shows an active site of vasculogenesis within an area of MM cell growth (yellow arrow). (4) H&E staining of a retrieved PCLS coated with BMSCs revealed the presence of a neosynthesized ECM inside the pores.
Similar articles
- Toward development of a novel NOD/SCID-based in vivo strategy to model multiple myeloma pathogenesis.
Bueno C, Lopes LF, Greaves M, Menendez P. Bueno C, et al. Exp Hematol. 2007 Oct;35(10):1477-8. doi: 10.1016/j.exphem.2007.06.012. Epub 2007 Aug 3. Exp Hematol. 2007. PMID: 17681665 No abstract available. - CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells.
Tai YT, Soydan E, Song W, Fulciniti M, Kim K, Hong F, Li XF, Burger P, Rumizen MJ, Nahar S, Podar K, Hideshima T, Munshi NC, Tonon G, Carrasco RD, Afar DE, Anderson KC. Tai YT, et al. Blood. 2009 Apr 30;113(18):4309-18. doi: 10.1182/blood-2008-10-183772. Epub 2009 Feb 4. Blood. 2009. PMID: 19196658 Free PMC article. Retracted. - Nonirradiated NOD/SCID-human chimeric animal model for primary human multiple myeloma: a potential in vivo culture system.
Huang SY, Tien HF, Su FH, Hsu SM. Huang SY, et al. Am J Pathol. 2004 Feb;164(2):747-56. doi: 10.1016/S0002-9440(10)63162-8. Am J Pathol. 2004. PMID: 14742278 Free PMC article. - Multiple myeloma-initiating cells.
Hosen N. Hosen N. Int J Hematol. 2013 Mar;97(3):306-12. doi: 10.1007/s12185-013-1293-0. Epub 2013 Feb 19. Int J Hematol. 2013. PMID: 23420183 Review. - Promises and challenges of MicroRNA-based treatment of multiple myeloma.
Tagliaferri P, Rossi M, Di Martino MT, Amodio N, Leone E, Gulla A, Neri A, Tassone P. Tagliaferri P, et al. Curr Cancer Drug Targets. 2012 Sep;12(7):838-46. doi: 10.2174/156800912802429355. Curr Cancer Drug Targets. 2012. PMID: 22671926 Free PMC article. Review.
Cited by
- Establishment of A Three-Dimensional Culture Condition for The U266 Cell Line Based on Peripheral Blood Plasma-Derived Fibrin Gels.
Jomehpour M, Khosravi M, Janfada M, Abroun S, Vahdat S. Jomehpour M, et al. Cell J. 2023 Apr 1;25(4):229-237. doi: 10.22074/cellj.2023.562849.1138. Cell J. 2023. PMID: 37210643 Free PMC article. - Animal Models of Multiple Myeloma Bone Disease.
Mehdi SH, Nafees S, Mehdi SJ, Morris CA, Mashouri L, Yoon D. Mehdi SH, et al. Front Genet. 2021 Jun 7;12:640954. doi: 10.3389/fgene.2021.640954. eCollection 2021. Front Genet. 2021. PMID: 34163520 Free PMC article. Review. - Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma.
Pisano M, Cheng Y, Sun F, Dhakal B, D'Souza A, Chhabra S, Knight JM, Rao S, Zhan F, Hari P, Janz S. Pisano M, et al. Front Immunol. 2021 Jun 2;12:667054. doi: 10.3389/fimmu.2021.667054. eCollection 2021. Front Immunol. 2021. PMID: 34149703 Free PMC article. Review. - JunB is a key regulator of multiple myeloma bone marrow angiogenesis.
Fan F, Malvestiti S, Vallet S, Lind J, Garcia-Manteiga JM, Morelli E, Jiang Q, Seckinger A, Hose D, Goldschmidt H, Stadlbauer A, Sun C, Mei H, Pecherstorfer M, Bakiri L, Wagner EF, Tonon G, Sattler M, Hu Y, Tassone P, Jaeger D, Podar K. Fan F, et al. Leukemia. 2021 Dec;35(12):3509-3525. doi: 10.1038/s41375-021-01271-9. Epub 2021 May 18. Leukemia. 2021. PMID: 34007044 Free PMC article. - Management of Myeloma Bone Lesions.
Du JS, Yen CH, Hsu CM, Hsiao HH. Du JS, et al. Int J Mol Sci. 2021 Mar 25;22(7):3389. doi: 10.3390/ijms22073389. Int J Mol Sci. 2021. PMID: 33806209 Free PMC article. Review.
References
- Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351:1860–1873. - PubMed
- Tassone P, Tagliaferri P, Fulciniti MT, Di Martino MT, Venuta S. Novel therapeutic approaches based on the targeting of microenvironment-derived survival pathways in human cancer: experimental models and translational issues. Curr Pharm Des. 2007;13:487–496. - PubMed
- Dalton W, Anderson KC. Synopsis of a roundtable on validating novel therapeutics for multiple myeloma. Clin Cancer Res. 2006;12:6603–6610. - PubMed
- Urashima M, Chen BP, Chen S, Pinkus GS, Bronson RT, Dedera DA, et al. The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood. 1997;90:754–765. - PubMed
- Yaccoby S, Barlogie B, Epstein J. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood. 1998;92:2908–2913. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical